Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Haemonetics Corp.
The AF Symposium in Boston Featured presentations of two trials of Johnson & Johnson/Biosense Webster’s Varipulse pulsed field ablation system and more safety data from the ADVENT trial of Boston Scientific’s Farapulse PFA.
The FDA approved Boston Scientific’s Farapulse pulsed field ablation system, as expected, at the end of January, and the company believes regulators in China and Japan will approve it later this year. Brad Sutton, Boston Scientific’s chief medical officer for atrial fibrillation solutions, told Medtech Insight why PFA will soon dominate the atrial fibrillation ablation market and how his company plans to be a leader in PFA.
Abbott is behind rivals Boston Scientific and Medtronic in the race to capture share of the emerging pulsed field ablation market. PFA is set to eventually become the most common cardiac ablation modality because it is safer than radiofrequency or cryoablation.
Leaders from the companies explain how they navigated to success with the world’s first CRISPR-based medicine – and avoided the pitfalls that claimed other programs.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.